CJC-1295 dosage in research

Amounts given to healthy adults

Teichman and colleagues studied single and multiple subcutaneous administrations of 30 or 60 micrograms per kilogram in healthy adults. Subcutaneous means beneath the skin. The work measured growth hormone, IGF-1 and persistence in blood.

Ionescu and Frohman gave healthy men single subcutaneous experimental amounts of 60 or 90 micrograms per kilogram to examine hormone pulsatility. These figures describe the cited experiments. Neither study established an approved treatment dose.

Detaching those numbers from their volunteers and measurements seems reckless to me. A weight-based amount in a supervised experiment cannot establish the safety of a fixed amount described online.

The separate mouse experiment

The GHRH-knockout mouse study gave 2 micrograms at 24-hour, 48-hour or 72-hour intervals. Administration every 24 hours normalized body weight and length; the longer intervals were progressively less effective. The animals lacked the hormone that normally initiates growth-hormone release.

That result belongs to a mouse growth experiment. Translating it into a human treatment schedule would require evidence that these data do not supply. The distinction is especially consequential when a search for CJC-1295 dosage brings together animal papers and personal accounts.

Administration methods

The cited human CJC-1295 work primarily used the subcutaneous route. Earlier related GRF work also examined intravenous administration. Swallowed peptide is extensively broken down, with negligible oral bioavailability. Those facts describe experimental methods and absorption; they provide no approved way to administer CJC-1295 as treatment.

The online accounts contain no validated regimen for CJC-1295 with ipamorelin. I reject extracting a regimen from those single-compound hormone studies. The immune concern, other safety questions and the difference between forms remain unresolved by quoting an experimental amount.